Maze Therapeutics (MAZE) Operating Income (2024 - 2026)

Maze Therapeutics has disclosed Operating Income across 3 years of filings, most recently posting -$26.6 million for Q1 2026.

• Operating Income for Q1 2026 came in at -$26.6 million, up 24.99% year-over-year; the trailing twelve-month figure through Mar 2026 was -$134.1 million (down 3601.85% YoY), and the FY2025 annual result was -$142.9 million, down 1374.18% from the prior year.
• Operating Income came in at -$26.6 million for Q1 2026 at Maze Therapeutics, up from -$38.1 million in the prior quarter.
• In the past five years, Operating Income ranged from a high of $139.6 million in Q2 2024 to a low of -$76.1 million in Q4 2024.
• The 3-year median for Operating Income is -$33.0 million (2025), against an average of -$17.6 million.
• Peak annual rise in Operating Income reached 49.99% in 2025, while the deepest fall reached 126.14% in 2025.
• Maze Therapeutics' Operating Income stood at -$76.1 million in 2024, then soared by 49.99% to -$38.1 million in 2025, then jumped by 30.23% to -$26.6 million in 2026.
• The last three Operating Income figures came in at -$26.6 million (Q1 2026), -$38.1 million (Q4 2025), and -$33.0 million (Q3 2025), per Business Quant data.